drugset / Trial / NCT00804414

Efficacy and Safety Study of Soluble Beta-1,3/1,6-glucan (SBG) Versus Placebo in Chronic Diabetic Foot Ulcers

NCT00804414 ↗

Phase 3 Completed 133 enrolled Biotec Pharmacon ASA
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Evaluation of efficacy and safety of SBG vs placebo in the treatment of chronic diabetic foot ulcers.

Timeline

Start
2008-10
Primary completion
2009-08
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Soluble Beta-1,3/1,6-glucan Unknown — Topical